Free Trial

Longeveron (LGVN) Competitors

Longeveron logo
$1.34 -0.04 (-2.55%)
As of 12:28 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LGVN vs. LXEO, VTYX, ANIX, SNTI, ZURA, ELUT, CLLS, CLYM, IZTC, and OCX

Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Lexeo Therapeutics (LXEO), Ventyx Biosciences (VTYX), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Zura Bio (ZURA), Elutia (ELUT), Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry.

Longeveron vs.

Longeveron (NASDAQ:LGVN) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.

Longeveron has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longeveron$2.23M8.99-$21.41M-$6.28-0.21
Lexeo Therapeutics$650K147.50-$66.39M-$3.30-0.88

In the previous week, Lexeo Therapeutics had 9 more articles in the media than Longeveron. MarketBeat recorded 17 mentions for Lexeo Therapeutics and 8 mentions for Longeveron. Lexeo Therapeutics' average media sentiment score of 0.45 beat Longeveron's score of 0.25 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Longeveron
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lexeo Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Longeveron has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Lexeo Therapeutics received 10 more outperform votes than Longeveron when rated by MarketBeat users. Likewise, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 94.74% of users gave Longeveron an outperform vote.

CompanyUnderperformOutperform
LongeveronOutperform Votes
18
94.74%
Underperform Votes
1
5.26%
Lexeo TherapeuticsOutperform Votes
28
100.00%
Underperform Votes
No Votes

Longeveron presently has a consensus price target of $8.67, indicating a potential upside of 546.77%. Lexeo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 599.45%. Given Lexeo Therapeutics' higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Longeveron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longeveron
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Lexeo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 19.1% of Longeveron shares are owned by insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lexeo Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. Lexeo Therapeutics' return on equity of -57.66% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Longeveron-967.49% -142.43% -100.84%
Lexeo Therapeutics N/A -57.66%-48.18%

Summary

Lexeo Therapeutics beats Longeveron on 13 of the 18 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGVN vs. The Competition

MetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$20.00M$6.47B$5.31B$8.31B
Dividend YieldN/A2.64%5.20%4.10%
P/E Ratio-0.218.5926.6919.58
Price / Sales8.99257.78393.58120.51
Price / CashN/A65.8538.2534.62
Price / Book0.506.396.744.47
Net Income-$21.41M$143.98M$3.23B$248.32M
7 Day Performance-5.63%-0.06%0.01%-1.26%
1 Month Performance-16.77%1.64%8.69%10.52%
1 Year Performance19.64%-0.73%18.36%8.53%

Longeveron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
3.2579 of 5 stars
$1.34
-2.5%
$8.67
+546.8%
+18.5%$20.00M$2.23M-0.2120News Coverage
Analyst Revision
LXEO
Lexeo Therapeutics
2.6961 of 5 stars
$2.63
-2.2%
$22.20
+744.1%
-79.7%$87.31M$650,000.00-0.8358News Coverage
Gap Up
High Trading Volume
VTYX
Ventyx Biosciences
2.4235 of 5 stars
$1.21
-2.4%
$10.00
+726.4%
-61.1%$86.11MN/A-0.5130Positive News
Gap Up
ANIX
Anixa Biosciences
1.7106 of 5 stars
$2.66
+1.9%
$9.00
+238.3%
+0.0%$85.64M$210,000.00-6.825Gap Up
SNTI
Senti Biosciences
1.6829 of 5 stars
$3.26
flat
$12.00
+268.1%
-16.3%$85.02M$2.56M-0.214Gap Up
ZURA
Zura Bio
2.7037 of 5 stars
$1.24
+2.5%
$14.33
+1,055.9%
-81.2%$84.79MN/A-2.343News Coverage
Analyst Revision
Gap Down
ELUT
Elutia
3.0113 of 5 stars
$1.82
-12.5%
$8.00
+339.6%
-49.7%$84.73M$23.71M-0.70180Gap Down
CLLS
Cellectis
2.7815 of 5 stars
$1.51
-4.4%
$7.00
+363.6%
-46.2%$83.93M$41.51M-1.16290News Coverage
Analyst Downgrade
CLYM
Climb Bio
2.6992 of 5 stars
$1.24
+4.2%
$10.00
+706.5%
N/A$83.79MN/A-0.589News Coverage
Positive News
Analyst Upgrade
Gap Up
IZTC
Invizyne Technologies
N/A$13.01
+4.0%
N/AN/A$81.34MN/A0.00N/A
OCX
OncoCyte
2.6287 of 5 stars
$2.81
-2.1%
$4.42
+57.2%
+18.2%$80.36M$1.88M-0.64120Analyst Forecast

Related Companies and Tools


This page (NASDAQ:LGVN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners